ORGO Organogenesis Holdings Inc
Price (delayed)
$2.85
Market cap
$377.84M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.13
Enterprise value
$398.35M
Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis's
Highlights
ORGO's debt is down by 10% year-on-year and by 4.5% since the previous quarter
The company's revenue rose by 3% QoQ
The quick ratio has declined by 8% year-on-year but it has grown by 2.2% since the previous quarter
Organogenesis Holdings's gross profit has decreased by 4% YoY but it has increased by 3.1% QoQ
ORGO's equity is down by 5% QoQ and by 2.9% YoY
The gross margin has declined by 2.2% year-on-year
Key stats
What are the main financial stats of ORGO
Market
Valuations
Earnings
Shares outstanding
132.58M
Market cap
$377.84M
Enterprise value
$398.35M
Price to book (P/B)
1.43
Price to sales (P/S)
0.84
EV/EBIT
N/A
EV/EBITDA
28.97
EV/Sales
0.89
Revenue
$448.39M
EBIT
-$10.96M
EBITDA
$13.75M
Free cash flow
$8.52M
Per share
Balance sheet
Liquidity
EPS
-$0.13
Free cash flow per share
$0.06
Book value per share
$1.99
Revenue per share
$3.38
TBVPS
$3.02
Total assets
$443.16M
Total liabilities
$179.66M
Debt
$110.99M
Equity
$263.5M
Working capital
$148.47M
Debt to equity
0.42
Current ratio
2.73
Quick ratio
2.29
Net debt/EBITDA
1.49
Margins
Efficiency
Dividend
EBITDA margin
3.1%
Gross margin
75.1%
Net margin
-3.7%
Operating margin
-2.5%
Return on assets
-3.6%
Return on equity
-6%
Return on invested capital
-3.1%
Return on capital employed
-3.1%
Return on sales
-2.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ORGO stock price
How has the Organogenesis Holdings stock price performed over time
Intraday
1.42%
1 week
12.2%
1 month
11.33%
1 year
16.33%
YTD
-30.32%
QTD
1.79%
Financial performance
How have Organogenesis Holdings's revenue and profit performed over time
Revenue
$448.39M
Gross profit
$336.94M
Operating income
-$11.02M
Net income
-$16.54M
Gross margin
75.1%
Net margin
-3.7%
Organogenesis Holdings's operating income has plunged by 187% from the previous quarter and by 168% YoY
Organogenesis Holdings's operating margin has shrunk by 186% QoQ and by 169% YoY
Organogenesis Holdings's gross profit has decreased by 4% YoY but it has increased by 3.1% QoQ
The company's revenue rose by 3% QoQ
Growth
What is Organogenesis Holdings's growth rate over time
Valuation
What is Organogenesis Holdings stock price valuation
P/E
N/A
P/B
1.43
P/S
0.84
EV/EBIT
N/A
EV/EBITDA
28.97
EV/Sales
0.89
The P/B is 81% below the 5-year quarterly average of 7.3 and 12% below the last 4 quarters average of 1.6
ORGO's equity is down by 5% QoQ and by 2.9% YoY
ORGO's P/S is 56% below its 5-year quarterly average of 1.9 and 17% below its last 4 quarters average of 1.0
The company's revenue rose by 3% QoQ
Efficiency
How efficient is Organogenesis Holdings business performance
The return on invested capital has dropped by 186% since the previous quarter and by 166% year-on-year
The return on sales has dropped by 183% since the previous quarter and by 167% year-on-year
Dividends
What is ORGO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ORGO.
Financial health
How did Organogenesis Holdings financials performed over time
ORGO's total assets is 147% greater than its total liabilities
The quick ratio has declined by 8% year-on-year but it has grown by 2.2% since the previous quarter
The current ratio has contracted by 7% YoY
ORGO's debt is 58% smaller than its equity
ORGO's debt is down by 10% year-on-year and by 4.5% since the previous quarter
The debt to equity is down by 7% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.